Zacks: Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) Will Announce Earnings of -$0.25 Per Share

Wall Street brokerages predict that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will announce ($0.25) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sunesis Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.17). Sunesis Pharmaceuticals reported earnings of ($0.44) per share in the same quarter last year, which indicates a positive year over year growth rate of 43.2%. The company is scheduled to report its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Sunesis Pharmaceuticals will report full year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.66) to ($1.48). For the next year, analysts expect that the company will report earnings of ($0.96) per share, with EPS estimates ranging from ($1.16) to ($0.80). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the previous year, the firm earned ($0.62) EPS.

Several research firms have weighed in on SNSS. Cantor Fitzgerald reiterated a “hold” rating and issued a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research note on Wednesday, September 27th. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a research note on Thursday, December 14th. They issued a “buy” rating and a $7.00 price objective on the stock. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Wells Fargo & Co upgraded shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price objective for the company from $2.86 to $2.48 in a research note on Monday, December 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $3.75.

In other news, Director Dayton Misfeldt acquired 400,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average cost of $2.00 per share, with a total value of $800,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Mpm Oncology Impact Management purchased 81,500 shares of Sunesis Pharmaceuticals stock in a transaction on Monday, November 6th. The stock was bought at an average cost of $2.77 per share, with a total value of $225,755.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 506,800 shares of company stock worth $1,091,282. 10.21% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN grew its position in shares of Sunesis Pharmaceuticals by 77.4% during the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 18,254 shares during the period. Virtu KCG Holdings LLC bought a new position in Sunesis Pharmaceuticals in the second quarter valued at approximately $208,000. Renaissance Technologies LLC lifted its stake in Sunesis Pharmaceuticals by 1.1% in the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. lifted its stake in Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. Institutional investors own 38.21% of the company’s stock.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up $0.06 during trading hours on Tuesday, hitting $3.69. 164,269 shares of the company traded hands, compared to its average volume of 132,614. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34. The stock has a market cap of $129.76, a P/E ratio of -2.11 and a beta of 1.55. Sunesis Pharmaceuticals has a fifty-two week low of $1.82 and a fifty-two week high of $4.45.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) Will Announce Earnings of -$0.25 Per Share” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/zacks-brokerages-anticipate-sunesis-pharmaceuticals-inc-snss-will-announce-earnings-of-0-25-per-share.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply